Stockreport

NantHealth Announces FDA Marketing Authorization of Omics Core?: The Nation’s First Tumor-Normal Mutation Profiling of Overall Tumor Mutational Burden from Whole Exome Sequencing in Solid ...

NantHealth, Inc.  (NH) 
Last nanthealth, inc. earnings: 11/7 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: nanthealth.com
PDF Landmark FDA clearance of whole exome sequencing in vitro diagnostic (IVD) test reporting overall tumor mutation burden (TMB) by sequencing 19,396 protein-coding genes ( [Read more]